Analyst Price Target is $22.00
▲ +38.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aerovate Therapeutics in the last 3 months. The average price target is $22.00, with a high forecast of $23.00 and a low forecast of $21.00. The average price target represents a 38.54% upside from the last price of $15.88.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Aerovate Therapeutics.